Need to get up to speed on Candida parapsilosis? Check out this new collaborative review on the subject in The Lancet. Congratulations to all authors! sciencedirect.com/science/articl…

So thrilled to see the online version of this comprehensive review paper. Thanks to everyone.

That's how creativity helps science @💉 🧪🧫⚗️🥼 Amir Arastehfar

Now published in the June issue of The Lancet Microbe Thanks Amir Arastehfar Farnaz, Ph.D. Candidate Tobias Hohl is now @fungalspore.bsky.social Dr. Clarissa J. Nobile Matthias Egger and many others. thelancet.com/journals/lanmi…

Upcoming📣Emerging infections due to rare Yeasts & Rare Molds. Join us on 3rd Oct, 5-7 PM Indian Time. Gagandeep Singh Ferry Hagen 🔬🧫🧬 Vinaykumar Hallur MBBS MD FECMM ISHAM CDC Emerging Infections ECMM Mycology Reference Centre Manchester Register here: events.teams.microsoft.com/event/9327ff83…

Neil Clancy Following your post, I am adding our original paper, where we intensively worked on genomic changes leading to petite phenotype, its implication using ex vivo and in vivo models, and epidemiological prevalence. Full story here, journals.asm.org/eprint/BA587GX…

The fungal pathogen, Candida glabrata, forms small, & slow-growing colonies, called “petite.” What is the clinical importance of petiteness? Researchers used multiple omics technologies & in vivo mouse models to find out. Find the results in mBio: asm.social/1vg

Had a pleasure to present one of our interesting stories about C.parapsilosis. Congrats to Amir Arastehfar for his great talk, and congratulations to all the The Mansour Lab members who did a great job in #IDWeek2023.

MDR pathogens can't prevail because they carry severe fitness costs. WRONG!!! It's time to raise awareness about the importance of MDR Candida parapsilosis.  Never underestimate this nasty phenotype.

Why?? Ok, check out our latest paper to understand why?!? Here is the link pubmed.ncbi.nlm.nih.gov/38380673/

1. Can echinocandin persistence determination in vitro among susceptible isolates inform their survival during echinocandin treatment in systemic infection? 2. Does determination of echinocandin persistence have any potential clinical values?

3. Can echinocandin persistence level impact the rate of echinocandin resistance? 4. How properly stratify tolerance using cfu counting and is there any method alternative to cfu counting? 5. Shall we include echinocandin persistence in clinical routine? What are the next steps?

Read it all here, secure-web.cisco.com/1twtn_Mnt2dNBS…

I am really happy to be in this incredible lab with such nice colleagues. Thanks everyone for making my birthday's double bycepts so cool... Jatin M. Vyas, MD, PhD Michael Mansour The Mansour Lab The Vyas Lab Keep it up...

Thrilled to receive the Travel Award 2025 from the Journal of Fungi MDPI 🎉 Honored to have my work recognized and excited to continue exploring antifungal resistance and fungal pathogenesis. Thanks to everyone who supported me on this journey! 🧫✨#Mycology #AntifungalResearch #TraveAward"

Global guideline for the diagnosis and management of candidiasis: an an initiative of the ECMM in cooperation with ISHAM & ASM Big congrats to Oliver Cornely and Rosanne Sprute for leading this tremendous effort & team sciencedirect.com/science/articl…

Fungal infections are 'taking over the world'. Can they be stopped? telegraph.co.uk/global-health/…